Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed COO
Appointed director
BridgeBio Pharma, Inc. (BBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/17/2023 144 Form 144 - Report of proposed sale of securities:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update - Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy , including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 , demonstrating a continued potentially best-in-class efficacy and well-tolerated safety profile, and a mean increase in annualized height velocity of 3.38cm/year with no treatment-related adverse events - Dosed the first participant in FORTIFY, a global Phase 3 study of BBP-418 in patients with limb girdle muscular dystrophy type 2I/R9 and met with the FDA to discuss the use of glycosylated alpha-dystroglycan levels as a surrogate endpoint; based on this ..."
07/26/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
07/19/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/18/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 8-K Quarterly results
05/17/2023 144 Form 144 - Report of proposed sale of securities:
05/17/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/04/2023 8-K Quarterly results
05/04/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/03/2023 144 Form 144 - Report of proposed sale of securities:
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/05/2023 144 Form 144 - Report of proposed sale of securities:
03/09/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among the Company, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several Underwriters listed on Schedule I thereto",
"Opinion of Goodwin Procter LLP regarding the issue of Common Stock being registered",
"BridgeBio Pharma Announces Proposed Public Offering of Common Stock",
"BridgeBio Pharma Announces Pricing of Public Offering of Common Stock"
03/09/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/06/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events",
"Corporate presentation, furnished herewith"
02/23/2023 8-K Quarterly results, Appointed a new director
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update"
02/08/2023 SC 13G STATE STREET CORP reports a 5.9% stake in INITIAL FILING BRIDGEBIO PHARMA INC
02/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
12/06/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
07/26/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy